Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma.

Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma.
Tohoku J Exp Med. 2019;249(1):19-28
Authors: Iwaki K, Fujiwara T, Ito T, Suzuki C, Sasaki K, Ono K, Saito K, Fukuhara N, Onishi Y, Yokoyama H, Fujimaki S, Tanaka T, Tamura H, Fujiwara M, Harigae H
Abstract
Multiple myeloma is the cancer of plasma cells. Along with the development of new and effective therapies, improved outcomes in patients with multiple myeloma have increased the interest in minimal residual disease (MRD) monitoring. However, the considerable heterogeneity of immunophenotypic and molecular markers of myeloma cells has limited its clinical application. 5-Aminolevulinic acid (ALA) is a natural compound in the heme biosynthesis pathway. Following ALA treatment, tumor cells preferentially accumulate porphyrins because of the differential activities of aerobic glycolysis, known as Warburg effect. Among various porphyrins, protoporphyrine IX is a strong photosensitizer; thus, ALA-based photodynamic diagnosis has been widely used in various solid cancers. Here, the feasibility of flow cytometry-based photodynamic detection of MRD was tested in multiple myeloma. Among various human cell lines of hematological malignancies, including K562 erythroleukemia, Jurkat T-cell leukemia, Nalm6 pre-B cell leukemia, KG1a myeloid leukemia, and U937 monocytic leukemia, human myeloma cell line, KMS18, a...

Source: The Tohoku Journal of Experimental Medicine - September 14, 2019 Category: Research Authors: Iwaki K, Fujiwara T, Ito T, Suzuki C, Sasaki K, Ono K, Saito K, Fukuhara N, Onishi Y, Yokoyama H, Fujimaki S, Tanaka T, Tamura H, Fujiwara M, Harigae H Tags: Tohoku J Exp Med Source Type: research